3 Australian Growth Stocks With Up To 64% Earnings Growth

Global bond markets are on edge as long dated US Treasury yields sit near multi decade highs, lifting borrowing costs for companies everywhere. Australian growth stocks with high insider ownership can look appealing in this kind of rate backdrop because managers with significant skin in the game often focus closely on capital discipline and sustainable expansion. This article highlights three such Australian opportunities from our high growth insider backed list.

The three stocks profiled next are only a snapshot, and the full screen identifies 111 more high growth, insider backed businesses that carry equally compelling stories. To go beyond this short list, head straight into the Fast Growing Stocks With High Insider Ownership screener to identify, filter, and analyze the highest conviction ideas that fit your own criteria.

PDI Gold (ASX:PDI)

Overview: PDI Gold is a West African focused gold producer and developer built around the large scale Kiniéro project and related assets.

Market Cap: A$4.8b

PDI Gold fits the Fast Growing Stocks With High Insider Ownership theme because the Kiniéro project gives management a clear production growth runway that insiders are heavily aligned to execute against.

"Kiniero is already running as a low cost operation with an AISC of US$1,043 per ounce and throughput that on strong days reaches between 7 million and 8 million tonnes per year."

For investors, the key consideration is how one unresolved funding and execution pressure ultimately shapes future cash generation from this portfolio.

That funding question is exactly what the full narrative for PDI Gold unpacks, revealing how management alignment could accelerate or stall Kiniéro’s long term cash engine.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops mesenchymal cell therapies like remestemcel L and related MPC programs aimed at severe inflammatory and cardiovascular conditions.

Operations: Mesoblast generates around $120 million in revenue from developing and commercializing its allogeneic cellular medicines platform.

Market Cap: A$2.8b

Mesoblast fits the Fast Growing Stocks With High Insider Ownership theme because its late stage remestemcel L and MPC programs provide growth optionality that is closely aligned with management’s cell therapy platform strategy.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, provides Mesoblast with a platform that may benefit if cell therapies gain wider medical adoption.

Mesoblast’s long term earnings power is closely linked to how one critical late stage program influences treatment practices in a large market.

That hinge point is exactly where the full narrative for Mesoblast steps in, mapping how approval risks, capital needs, and adoption curves could accelerate Mesoblast’s opportunity or keep it stalled.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals develops and commercialises radiopharmaceutical imaging agents and therapies that help doctors precisely detect and target cancers worldwide.

Operations: Telix generates about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, with most earnings coming from the United States.

Market Cap: A$5.3b

Telix Pharmaceuticals attracts attention in this screener because its late stage radiopharmaceutical pipeline lines up neatly with management’s push for rapid, targeted growth in cancer imaging and treatment.

"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year."

What happens if a single pressure point in that next wave of prostate cancer trials and regulatory calls reshapes expectations for Telix’s growth engine?

That inflection risk is exactly what the full narrative for Telix Pharmaceuticals unpacks, showing where Telix Pharmaceuticals could see its momentum accelerate or stall as the next trial calls land.

Seeking Alternatives Before Momentum Flies

Fresh opportunities can move from quiet to crowded quickly. Use these focused screens to spot potential breakouts while they are still under the radar for now, act now.

• Target dependable income streams by scanning a curated pool of potential high yield payers through the 3 dividend fortresses before payouts and prices get fully caught by the crowd.
• Spot potential long runway compounders by reviewing a hand picked 16 high quality undiscovered gems list that may still be flying under most radars while it matters.
• Position ahead of possible infrastructure momentum by checking the curated 39 power grid technology and infrastructure stocks backed by companies aligned to long term grid and electrification spending themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com